ORTX - Orchard Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.217M

Cash

146.3M

Avg Qtr Burn

-21.47M

Short % of Float

0.00%

Insider Ownership

5.40%

Institutional Own.

34.65%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Libmeldy / OTL-200 (ex vivo autologous gene therapy) Details Rare diseases, Central nervous system illness, Rare genetic disease	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-203 (ex vivo autologous gene therapy) Details Metabolic disorder, Mucopolysaccharidosis Type 1	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-201 (ex vivo autologous gene therapy) Details Metabolic disorder, Eye disease , Sanfilippo Syndrome, Mucopolysaccharidosis type IIIA	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OTL-103 (ex vivo autologous gene therapy) Details WAS (Wiskott Aldrich syndrome)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.